Xenetic Biosciences, Inc.
XBIO evidence brief
What we can confirm
- Market Cap:
- $9.1M
What it means
What to watch
Prepared research question
What matters most for XBIO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XBIO
Xenetic Biosciences, Inc. (XBIO) is a pre-revenue, development-stage biopharmaceutical company focused on next-generation biologic drugs, currently executing a share exchange agreement with Santersus AG to create a Nasdaq-listed clinical-stage company targeting neutrophil extracellular traps (NETs).
Key risk: No approved products
Market Cap
$9.1M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Xenetic Biosciences, Inc. (XBIO) is a pre-revenue, development-stage biopharmaceutical company focused on next-generation biologic drugs, currently executing a share exchange agreement with Santersus AG to create a Nasdaq-listed clinical-stage company targeting neutrophil extracellular traps (NETs).
- Total revenue of $0.7M and net income of -$0.9M as of 2026-06-30 [sec].
- Shareholders' equity of $6.1M as of 2026-06-30 [sec].
- None of its drug candidates have received regulatory marketing authorization in the U.S. or elsewhere [sec_mda · as of 2026-08-06].
- Announced a definitive share exchange agreement with Santersus AG on 2026-09-16 to create a combined company focused on NET-targeting therapeutics [news · published 2026-09-16].
- Raised net proceeds of approximately $4.0 million in an underwritten public offering of common stock in October 2025 [sec_mda · as of 2026-08-06].
What works
- The company has a strategic collaboration with Santersus AG that is expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on a single high-impact therapeutic target (NETs) [news · published 2026-09-16].
- Xenetic continues to receive ongoing royalties from a license of its legacy PolyXen technology [sec_mda · as of 2026-08-06].
- Management believes existing resources will be adequate to fund operations for at least twelve months from the date of the financial statements [sec_mda · as of 2026-08-06].
What to weigh
- The company has incurred substantial losses since inception and expects to continue incurring operating losses in the near-term [sec_mda · as of 2026-08-06].
- None of its drug candidates have received regulatory marketing authorization in the U.S. or any other country [sec_mda · as of 2026-08-06].
- The share exchange with Santersus is subject to risks, including failure to obtain stockholder approval or other conditions to closing [sec · filed 2026-09-23].
- The company anticipates it will need additional capital in the long-term to pursue its business initiatives [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
No drug candidates have received regulatory approval
“To date, none of our drug candidates have received regulatory marketing authorization or approval in the U.S. by the Food and Drug Administration nor in any other countries or territories by any applicable agencies.”
SEC MD&A · August 6, 2026
Share exchange agreement with Santersus
“Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics”
News · September 16, 2026
Substantial losses since inception
“We have incurred substantial losses since our inception, and we expect to continue to incur operating losses in the near-term.”
SEC MD&A · August 6, 2026
Net proceeds from public offering
“the Company raised net proceeds of approximately $4.0 million in an underwritten public offering of common stock in October 2025.”
SEC MD&A · August 6, 2026
Risks & what to watch (4)›
Key risks
- No approved products — None of its drug candidates have received regulatory marketing authorization in the U.S. or elsewhere [sec_mda · as of 2026-08-06].
- Ongoing operating losses — The company has incurred substantial losses since inception and expects to continue incurring operating losses [sec_mda · as of 2026-08-06].
- Share exchange closing risk — The Santersus acquisition is subject to conditions including stockholder approval, which may not be satisfied [sec · filed 2026-09-23].
- Long-term capital need — The company anticipates it will need additional capital in the long-term to pursue business initiatives [sec_mda · as of 2026-08-06].
What to watch
- Stockholder vote on the Santersus share exchange agreement [sec · filed 2026-09-23].
- Progress of any drug candidates toward regulatory milestones [sec_mda · as of 2026-08-06].
- Ability to secure additional long-term capital [sec_mda · as of 2026-08-06].
- Royalty revenue from the PolyXen technology license [sec_mda · as of 2026-08-06].
Sources: News · SEC filings · SEC MD&A · Generated October 2, 2026 · How we verify sources →
Run Xenetic Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Xenetic Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$446K
| Holder | Shares | Value |
|---|---|---|
| renaissance technologies llc | 137,440 | $368K |
| geode capital management, llc | 21,441 | $57K |
| vanguard capital management llc | 6,731 | $18K |
| tower research capital llc (trc) | 806 | $2K |
| jtc employer solutions trustee ltd | 2,700 | $7 |
| darwin wealth management, llc | 2 | $5 |
Short Interest
as of May 22, 2026- % of float
- 0.3%
- Days to cover
- 0.5
- Shares short
- 7,266
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XBIO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Xenetic Biosciences, Inc.?
Xenetic Biosciences, Inc. (XBIO) is a pre-revenue, development-stage biopharmaceutical company focused on next-generation biologic drugs, currently executing a share exchange agreement with Santersus AG to create a Nasdaq-listed clinical-stage company targeting neutrophil extracellular traps (NETs).
Who is the CEO of Xenetic Biosciences, Inc.?
Mr. James F. Parslow is the chief executive officer of Xenetic Biosciences, Inc. (XBIO).
Where is Xenetic Biosciences, Inc. headquartered?
Xenetic Biosciences, Inc. (XBIO) is headquartered in Framingham, MA, United States.
What therapeutic areas does Xenetic Biosciences, Inc. focus on?
Xenetic Biosciences, Inc. develops therapies across Oncology, Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.